CagriSema submissions are expected in 2025-2026
A randomized clinical trial shows that only 13% of people discontinued semaglutide compared to 27.6% for liraglutide in a 68-week trial
"My doctor told me that it was likely a rare reaction
Theres a lot more to explore. For now, though, the focus remains on integrating GLP-1 inhibitor therapy into standard care for OSA patients while managing expectations
The adverse events presented [in this study] are not new, Mahyar Etminan, PharmD, associate professor of medicine in the department of ophthalmology and visual sciences at the University of British Columbia and CEO of Epilytics, an epidemiology consulting group, told Health
These problems can be detected in patients with hypertension